The different prevalence of BRCA mutated patients, especially BRCA1 mutated, may account for some of the differences observed in clinico-pathological characteristics between the groups, with BC first patients showing younger age at 1st and 2nd diagnoses, more aggressive OC features and a higher prevalence of TNBC. This evidence concerns the gene BRCA1 and breast cancer.